Amazon.com Inc vs Bristol-Myers Squibb Co — how do they compare? Amazon.com Inc trades at $246.52 (market cap $2.64T), while Bristol-Myers Squibb Co trades at $58.47 (market cap $117.58B). The key difference: Amazon.com Inc is far larger — about 22.5× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays a 4.38% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | BMY | |
|---|---|---|
Market Cap | $2.64T | $117.58B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $62.37 |
52-Week Low | $198.79 | $42.60 |
Enterprise Value | $2.71T | $153.52B |
Dividend Yield | — | 4.38% |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $244.19, down 0.47% on the day but maintains strong bullish technical momentum with support at $241. The company demonstrates robust fundamentals with 2025 revenue of $716.92B and net income of $77.67B, representing 10.83% profit margin. Recent Q1 2026 earnings beat expectations with EPS of $2.78 versus $1.63 expected, while analyst consensus remains overwhelmingly positive with 88.3% buy ratings.
Amazon's outlook remains favorable with continued revenue growth and expanding profitability, though significant capital expenditures for AI infrastructure and competitive pressures in e-commerce present risks. The stock trades at a P/E of 29.35, offering growth potential relative to the consensus price target of $320.75, representing 31% upside from current levels.
Bristol Myers Squibb (BMY) trades at $57.58, down 0.62% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 70.46% gross margin and 15.01% net income margin, though it faces a patent cliff risk. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.58 surpassing the $1.42 estimate. Analyst consensus shows a mixed but leaning positive view with 46% buy ratings and a $60 price target.
BMY offers value with a reasonable P/E of 16.13 and attractive 4.3% dividend yield, supported by 36 years of uninterrupted payments. However, investors must weigh the patent expiration headwinds against the company's growth portfolio, which now represents 54.1% of revenues. The stock presents a balanced opportunity for income-focused investors with moderate growth potential amid ongoing business transformation.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →